A new partnership will bring three new medications to the Middle East and North Africa, including an Ocrevus biosimilar drug ...

The patent comes months after Immunic Therapeutics announced CALLIPER study results, which tested vidofludimus calcium in ...

Sept 2 (Reuters) - Sanofi's (SASY.PA), opens new tab most advanced multiple sclerosis drug candidate has missed the main goal of two late-stage trials to treat relapsing forms of the disease, but in a ...

Sales of Biogen’s BIIB key multiple sclerosis (“MS”) drugs like Tecfidera and Tysabri and spinal muscular atrophy (SMA) treatment, Spinraza, are being hurt due to competitive pressure, which is ...

Quantum BioPharma Ltd. announced the completion of dosing in 90-day oral toxicity and toxicokinetic studies for its drug Lucid-21-302 (Lucid-MS), aimed at treating Multiple Sclerosis (MS). This ...

Sanofi has agreed to pay $315 million to settle claims that it slowed the development of a multiple sclerosis drug to avoid paying investors after the company acquired Genzyme Corp. The lawsuit, filed ...

With two late-stage programs set to read out in the next 48 months, Biogen is translating its wealth of experience in ...

A Canadian-led international research team, spearheaded by Dr. Fang Liu at the Centre for Addiction and Mental Health (CAMH) has received nearly $800,000 US ($1,137,868 CAD) in new funding to advance ...

FRANKFURT, Jan 13 (Reuters) - Merck KGaA said on Tuesday it had bought the rights to develop and market an experimental multiple sclerosis (MS) drug from British biotech company Apitope, expanding its ...

A generation ago, most people with multiple sclerosis could expect to rely on walkers and wheelchairs or be limited to their bed within 15 years of diagnosis. Today, UC San Francisco’s discoveries are ...

A Sanofi experimental drug for multiple sclerosis delayed disability progression in a late-stage trial, but failed to reduce episodes of new or worsening symptoms compared to an existing treatment in ...

In the United States, out-of-pocket (OOP) costs of brand-name medications for neurological disorders increased significantly from 2012 to 2021, with the largest hikes in multiple sclerosis (MS) drugs, ...